34789 Efficacy and safety of ruxolitinib cream for the treatment of vitiligo: Week 24 pooled analysis of the TRuE-V phase 3 studies

Abstract

Vitiligo is a chronic autoimmune skin disease. A cream formulation of the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib demonstrated substantial repigmentation in a 52-week, phase 2, randomized study in adult patients with vitiligo (NCT03099304). Two phase 3, double-blind, controlled studies (TRuE-V1 [NCT04052425]; TRuE-V2 [NCT04057573]) were conducted in North America and Europe. Patients ≥12 years old diagnosed with nonsegmental vitiligo with depigmentation covering ≤10% total body surface area (BSA), including facial and total Vitiligo Area Scoring Index (F-VASI/T-VASI) scores ≥0.5/≥3, were eligible.